{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:21:59Z","timestamp":1778048519752,"version":"3.51.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To document prophylactic practices, infection patterns, and disease burden to inform strategies for CMV management in high-risk kidney transplant recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort of 311 consecutive CMV D+\/R- kidney recipients were enrolled from 7 Canadian programs over 4 years (2018-2021) to provide data on demographic, clinical, therapeutic and health resource use during the 1st year post-transplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Themedian age was 58 (46, 67) years, 69% were male, and 53% were White. Diabetes was the principal cause of kidney failure (19%). 208 (69%) received a deceased donor graft; 76 (24%) had ATG induction, and 84% had maintenance therapy with tacrolimus and MMF\/MPA \u00b1 prednisone. All received antiviral prophylaxis, 90% with valganciclovir, for a median of 180 days. 106 (34%) developed CMV viremia (median peak viral load 14,224 IU\/ml) at a median of 218 days, of whom 46 (43%) had CMV disease and 15 (14%) had recurrent infection. Myelotoxicity occurred in 121 (39%) patients at a median of 88 days, lasting a median of 30 days. Opportunistic infections occurred in 119 patients (38%) at a median of 53 days. 141 patients (45%) were hospitalized, 50 (16%) more than once. 20 patients (6%) had biopsy-confirmed rejection, and 293 (94%) were alive with a functioning graft at 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Current prophylaxis strategies fail to prevent CMV infection in 34% of high-risk patients. Myelotoxicity, opportunistic infection, reduced immunosuppression, and hospitalization remain common and serious complications. More effective and less toxic personalized treatment strategies are required to minimize these risks and burdens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1618748","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:12:38Z","timestamp":1758168758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical management and burden of cytomegalovirus in D+\/R-Kidney transplant recipients in Canada"],"prefix":"10.3389","volume":"16","author":[{"given":"John","family":"Gill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"House","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain","family":"Chagla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Tchervenkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Joseph","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Vinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Keown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia Lai Wing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Ghakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation","volume":"17","author":"Fishman","year":"2017","journal-title":"Am J Transpl"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0943-1","article-title":"New developments in the management of cytomegalovirus infection after transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2054358118799692","DOI":"10.1177\/2054358118799692","article-title":"Incidence rate of post-kidney transplant infection: A retrospective cohort study examining infection rates at a large Canadian multicenter tertiary-care facility","volume":"5","author":"Cowan","year":"2018","journal-title":"Can J Kidney Health Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15183","article-title":"Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis","volume":"19","author":"Leeaphorn","year":"2019","journal-title":"Am J Transpl"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000438197.38413.f2","article-title":"Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients","volume":"97","author":"Jamal","year":"2014","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","author":"Razonable","year":"2013","journal-title":"Am J Transpl"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transpl"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13483","article-title":"Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence","volume":"23","author":"Raval","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transpl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23539","article-title":"High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy","volume":"85","author":"Harvala","year":"2013","journal-title":"J Med Virol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12594","article-title":"Cytomegalovirus infection in solid organ transplant recipients","author":"Lumbreras","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113060","article-title":"Risk factors for CMV and BK infections in an elderly veteran population following kidney transplantation: implications for immunosuppression induction and management","volume":"11","author":"Thorndyke","year":"2023","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2024.1393838","article-title":"Interactions of TTV with BKV, CMV, EBV, and HHV-6A and their impact on post-transplant graft function in kidney transplant recipients","volume":"3","author":"Rosiewicz","year":"2024","journal-title":"Front Transpl"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13080","article-title":"Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes","volume":"21","author":"Jorgenson","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01790215","article-title":"Risk stratification for rejection and infection after kidney transplantation","volume":"10","author":"Cipp\u00e0","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181949e09","article-title":"Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines","volume":"87","author":"Dmitrienko","year":"2009","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transpl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.03.020","article-title":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","volume":"29","author":"Razonable","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100587","DOI":"10.1016\/j.trre.2020.100587","article-title":"Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials","volume":"35","author":"Raval","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00015-13","article-title":"Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation","volume":"26","author":"Razonable","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ebiom.2015.06.004","article-title":"Cytomegalovirus: why viral dynamics matter","volume":"2","author":"Mueller","year":"2015","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ebiom.2015.05.003","article-title":"Clinical application of variation in replication kinetics during episodes of post-transplant cytomegalovirus infections","volume":"2","author":"Lodding","year":"2015","journal-title":"EBioMedicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12773","article-title":"Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey","volume":"19","author":"Navarro","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100875","DOI":"10.1016\/j.trre.2024.100875","article-title":"Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update","volume":"38","author":"Ruiz-Arabi","year":"2024","journal-title":"Transplant Rev (Orlando)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00692.x","article-title":"Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report","volume":"5","author":"Preiksaitis","year":"2005","journal-title":"Am J Transpl"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12786","article-title":"A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients","volume":"20","author":"Suresh","year":"2016","journal-title":"Pediatr Transpl"},{"key":"B29","unstructured":"Common terminology criteria for adverse events (CTCAE)\n          \n          \n          \n          2010"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40139-020-00213-x","article-title":"Leveraging computational modeling to understand infectious diseases","volume":"8","author":"Jenner","year":"2020","journal-title":"Curr Pathobiol Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"ofx172","DOI":"10.1093\/ofid\/ofx172","article-title":"Mathematical modeling of \u201cChronic\u201d Infectious diseases: unpacking the black box","volume":"4","author":"Fojo","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1302627","article-title":"Viral load kinetics and the clinical consequences of cytomegalovirus in kidney transplantation","volume":"14","author":"Dobrer","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0225-5","article-title":"Modulation of innate and adaptive immunity by cytomegaloviruses","volume":"20","author":"Berry","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13977","article-title":"Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021","volume":"24","author":"Kotton","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa125","article-title":"Donor graft cytomegalovirus serostatus and the risk of arterial and venous thrombotic events in seronegative recipients after non-thoracic solid organ transplantation","volume":"72","author":"Belga","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1190794","article-title":"Long-term CMV monitoring and chronic rejection in renal transplant recipients","volume":"13","author":"Ishikawa","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.athplu.2022.03.003","article-title":"Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events","volume":"48","author":"Rodr\u00edguez-Goncer","year":"2022","journal-title":"Atheroscler Plus"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14227","article-title":"Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease","volume":"26","author":"Belga","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14183","article-title":"Slaying the \u201cTroll of Transplantation\u201d-new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023","volume":"26","author":"Kotton","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"CD003774","DOI":"10.1002\/14651858.CD005133.pub4","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"5","author":"Vernooij","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"10332","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: A pre-COVID-19 survey from the working group of the European society for organ transplantation","volume":"35","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"key":"B47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","author":"Kotton","year":"2013","journal-title":"Am J Transpl"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002464","article-title":"The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation","volume":"72","author":"Dmitrienko","year":"2007","journal-title":"Kidney Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2024.05.009","article-title":"Prevention and management of cytomegalovirus infection and disease in kidney transplant: A consensus statement of the Transplantation Society of Taiwan","volume":"124","author":"Chung","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181bc0301","article-title":"Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance","volume":"89","author":"van der Beek","year":"2010","journal-title":"Transplantation"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318200b9f0","article-title":"Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients","volume":"91","author":"Boillat Blanco","year":"2011","journal-title":"Transplantation"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14000","article-title":"Burden of neutropenia and leukopenia among adult kidney transplant recipients: A systematic literature review of observational studies","volume":"25","author":"Raval","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.05.020","article-title":"Variants in mycophenolate and CMV antiviral drug pharmacokinetic and pharmacodynamic genes and leukopenia in heart transplant recipients","volume":"40","author":"Oreschak","year":"2021","journal-title":"J Heart Lung Transpl"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13775","article-title":"Management of drug-induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: A comprehensive review","volume":"47","author":"Baradaran","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1987","article-title":"Ganciclovir-resistant cytomegalovirus infection in abdominal solid organ transplant recipients: case series and review of the literature","volume":"37","author":"Rolling","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02699.x","article-title":"Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study","volume":"9","author":"Zafrani","year":"2009","journal-title":"Am J Transpl"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e14766","DOI":"10.1111\/ctr.14766","article-title":"Granulocyte colony-stimulating factor with or without immunosuppression reduction in neutropenic kidney transplant recipients","volume":"36","author":"Sandal","year":"2022","journal-title":"Clin Transpl"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9100","article-title":"A new antiviral option for cytomegalovirus prevention after kidney transplant","volume":"330","author":"Raglow","year":"2023","journal-title":"JAMA"},{"key":"B60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: A randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: A systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15971020","article-title":"Long-term infectious complications of kidney transplantation","volume":"17","author":"Agrawal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B64","volume-title":"Canadian Organ Replacement Register (CORR)","year":"2024"},{"key":"B65","volume-title":"Canadian Blood Services","year":"2017"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1712602","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618748\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:08:12Z","timestamp":1760450892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618748\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2025.1618748"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1618748","relation":{"correction":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1712602","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1618748"}}